<img alt="" src="https://secure.soil5hear.com/223550.png" style="display:none;">
Skip to content
CDX

SU-DHL-8

Description

SU-DHL-8 (Lymphoma CDX Model) 

The SU-DHL-8 cell line was derived from diffuse large B-cell lymphoma (DLBCL). It provides a reproducible system for hematology drug discovery. SU-DHL-8 reflects aggressive B-cell malignancy biology. Its consistent growth supports translational lymphoma pipelines. 

Key Features: 

  • Derived from diffuse large B-cell lymphoma. 
  • Represents aggressive B-cell disease. 
  • Suspension culture phenotype. 
  • Tumorigenic in xenografts. 

Applications: 
SU-DHL-8 is used in preclinical testing of novel lymphoma therapies. It supports biomarker validation and drug resistance research. Researchers apply it to study B-cell signaling pathways. Its reproducibility ensures value for translational hematology research.

Details
Tumor Type
Lymphoma
Tumor Subtype
DLBCL (GCB)
Organism
Human
Mouse Sex
Female
Mouse Strain
Athymic Nude
Mutated Genes
BRAF
Mutation: p.T599dup
Effect: Inframe Insertion
Impact: Pathogenic
TP53
Mutation: p.R249G
Effect: Missense Variant
Impact: Likely Pathogenic & Uncertain Significance & Conflicting Interpretations Of Pathogenicity
Mutation: p.Y234N
Effect: Missense Variant
Impact: Pathogenic & Likely Pathogenic
Lumin Data
Proteomics RNASeq WES
Expression Data
Growth Curve
View on Lumin